Home
About
Overview
Sharing Data
ORCID
Help
History (5)
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of The American Association for Thoracic Surgery Task Force for Lung Cancer Screening and Surveillance.
Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders.
Ethical and policy issues in genetic testing.
The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
See All 5 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders.
Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders. Cancer Treat Rev. 2014 Feb; 40(1):197-203.
View in:
PubMed
subject areas
Animals
Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung
Eye
Eye Diseases
Humans
Lung Neoplasms
Molecular Targeted Therapy
Protein Kinase Inhibitors
authors with profiles
Marina Chiara Garassino